<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5082">
  <stage>Registered</stage>
  <submitdate>14/07/2015</submitdate>
  <approvaldate>14/07/2015</approvaldate>
  <nctid>NCT02506569</nctid>
  <trial_identification>
    <studytitle>ProMRI 3T ENHANCED Master Study</studytitle>
    <scientifictitle>ProMRI 3T ENHANCED Master Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TA109</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Safety of MR (Magnetic Resonance)-Conditional ICDs</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Implantable Cardioverter Defibrillator therapy
Other interventions - Magnetic Resonance Imaging (MRI)

Treatment: devices: Implantable Cardioverter Defibrillator therapy
Tachycardia Fast Heart Beat

Other interventions: Magnetic Resonance Imaging (MRI)
MRI scan of the head and lower body parts

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serious Adverse Device Effect (SADE)-free rate of implantable cardioverter defibrillators and leads possibly or securely related to the MRI procedure</outcome>
      <timepoint>1 Month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Increase in pacing thresholds ratios measured between 1-month post-MRI and pre-MRI - Evaluate the percentage of ICD leads with an increase in the pacing threshold ratio measured between the Pre-MRI and 1-month post-MRI</outcome>
      <timepoint>1 Month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Decrease in sensing amplitude ratios between 1-month post-MRI and pre-MRI - Evaluate the percentage of ICD leads with a decrease in the sensing amplitude ratio measured between the Pre-MRI and 1-month post-MRI</outcome>
      <timepoint>1 Month</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Implanted with Implantable Cardioverter Defibrillator (ICD) system according to
             Clinical Investigational Plan (CIP)

          -  ICD system was implanted in the pectoral region

          -  Implantation at least 5 weeks prior to enrollment date

          -  Patient body height = 140 cm

          -  Age = 18 years

          -  Right Ventricular pacing threshold (at 0.4 ms) measurable and = 2.0 V

          -  Written informed consent

          -  Able and willing to complete MRI testing

          -  Able and willing to complete all testing required by the clinical protocol

          -  Available for all follow-up visits at the investigational site</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Standard contraindication for MRI scans

          -  Patient shows signs of a twiddler's syndrome, i.e. fiddles with implant

          -  Explantation, exchange or reposition of ICD or lead within 5 weeks prior to enrollment
             date

          -  Charging status of the battery is Elective Replacement Indicator (ERI) or End of
             Service (EOS)

          -  MRI scan within 5 weeks prior to enrollment date

          -  R-wave sensing amplitude &lt; 6.5 millivolt

          -  Lead impedance less than 200 or greater than 1500 Ohm

          -  Life expectancy of less than six months

          -  Cardiac surgery in the next six months

          -  Pregnant or breastfeeding

          -  Participation in another interventional clinical investigation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>129</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Royal North Shore Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <postcode> - Bedford Park</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>St. Pölten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Düsseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Göttingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biotronik SE &amp; Co. KG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The investigation is designed to provide supporting evidence for the clinical safety of the
      Biotronik's new Implantable Cardioverter Defibrillator systems when used under specific 3
      Tesla MR conditions .</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02506569</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rainer Zbinden, Dr.</name>
      <address>Triemli Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Gabriel Knop, Dr.</name>
      <address />
      <phone>00493068905</phone>
      <fax />
      <email>Enhanced@biotronik.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>